Burning Rock Biotech Ltd
BNR6.360USD
+0.690+12.17%
Horário de mercado （ET）Cotações atrasadas em 15 min
57.42MValor de mercado
PerdaP/L TTM
Mais detalhes de Burning Rock Biotech Ltd Empresa
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Informações da empresa
Código da empresaBNR
Nome da EmpresaBurning Rock Biotech Ltd
Data de listagemJun 12, 2020
CEOMr. Yusheng Han
Número de funcionários674
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
EndereçoNo. 5 Xingdao Ring Road North
CidadeGUANGZHOU
Bolsa de valoresXetra
PaísChina
Código postal510005
Telefone
Sitehttps://www.brbiotech.com/
Código da empresaBNR
Data de listagemJun 12, 2020
CEOMr. Yusheng Han
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Mr. Gang Lu
Mr. Gang Lu
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Detalhamento da receita
FY2019
FY2018
Sem dados
Por RegiãoCNY
Nome
Receita
Proporção
China (Mainland)
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 13 de jun
Atualizado em: sex, 13 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Northern Light Venture Capital
11.67%
Kynam Capital Management LP
11.01%
Lyfe Capital
9.23%
China Merchants Bank Co Ltd
5.12%
Lilly Asia Ventures
4.85%
Other
58.11%
Investidores
Investidores
Proporção
Northern Light Venture Capital
11.67%
Kynam Capital Management LP
11.01%
Lyfe Capital
9.23%
China Merchants Bank Co Ltd
5.12%
Lilly Asia Ventures
4.85%
Other
58.11%
Tipos de investidores
Investidores
Proporção
Private Equity
20.90%
Hedge Fund
12.92%
Investment Advisor/Hedge Fund
7.58%
Bank and Trust
5.13%
Venture Capital
4.85%
Sovereign Wealth Fund
4.49%
Corporation
3.92%
Investment Advisor
3.56%
Research Firm
0.45%
Other
36.20%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
59
5.76M
63.80%
+1.00M
2025Q1
66
5.77M
63.83%
+940.56K
2024Q4
74
5.50M
64.55%
+928.80K
2024Q3
93
5.26M
61.71%
+353.76K
2024Q2
109
5.27M
61.79%
+40.23K
2024Q1
122
5.30M
62.18%
-174.69K
2023Q4
137
5.24M
61.49%
-310.76K
2023Q3
208
5.51M
64.24%
-866.01K
2023Q2
220
5.57M
64.96%
-832.63K
2023Q1
226
5.60M
65.29%
-882.42K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Northern Light Venture Capital
1.05M
11.67%
--
--
Mar 31, 2025
Kynam Capital Management LP
994.88K
11.01%
--
--
Mar 31, 2025
Lyfe Capital
833.84K
9.23%
--
--
Mar 31, 2025
China Merchants Bank Co Ltd
462.99K
5.12%
--
--
Mar 31, 2025
Lilly Asia Ventures
438.42K
4.85%
+438.42K
--
Dec 31, 2023
GIC Private Limited
405.64K
4.49%
+405.64K
--
Dec 31, 2023
MFS Investment Management
367.00K
4.06%
-2.73K
-0.74%
Mar 31, 2025
Quantum Boundary Holdings Ltd
353.92K
3.92%
+350.62K
+10637.83%
Mar 31, 2025
Fidelity International
280.90K
3.11%
--
--
Mar 31, 2025
CRCM L.P.
226.29K
2.5%
-99.68K
-30.58%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Avantis Responsible Emerging Markets Equity ETF
0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
Avantis Responsible Emerging Markets Equity ETF
Proporção0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Proporção0%
SPDR S&P Emerging Markets Small Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Data
Tipo
Proporção
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
Apr 26, 2024
Merger
10<1
